The effects of anti-CD20 therapy on TFH cells in relapsing-remitting MS
This study presented at ECTRIMS examines the effect of anti-CD20 therapy on T follicular helper (TFH) cells in relapsing-remitting MS. Sahla El Mahdaoui explains how they found a reduction in CD25-negative TFH cells after treatment. These cells are enriched in cerebrospinal fluid in untreated MS patients and linked to disease activity. The findings suggest CD25-negative TFH cells may play a role in MS progression and treatment response.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in